ReviewNeuro-oncology advances
The immune landscape of cerebrospinal fluid across brain malignancies.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrospinal fluid (CSF) is an active immunological interface within the central nervous system, reflecting and shaping tumor-immune interactions that are often invisible in peripheral blood. Accumulating evidence demonstrates that CSF immune remodeling is highly malignancy-specific rather than uniform across brain cancers. In this review, we synthesize recent advances in CSF immune profiling across gliomas, primary CNS lymphomas, brain metastases, and leptomeningeal metastases, highlighting how each disease programs distinct cellular and cytokine circuits. Gliomas are characterized by myeloid skewing and IL-6-associated inflammation, CNS lymphomas by IL-10/CXCL13-driven B-cell-supportive niches, brain metastases by primary tumor-imprinted inflammatory signatures, and leptomeningeal metastases by profound macrophage dominance and complement-mediated immune reprogramming. Importantly, CSF alterations are not merely correlative but mechanistically linked to immune evasion, disease progression, and therapeutic responsiveness. We further discuss translational applications of CSF analysis for molecular stratification, immune monitoring, and treatment response assessment, and critically evaluate the emerging role of CSF-directed therapeutic strategies. Collectively, this review positions CSF as a biologically and clinically integrated compartment with growing relevance for precision neuro-oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.